News
Leading ovarian cancer organization announces 2017 honorees
Largest private funder of ovarian cancer research recognizes top researchers and community leaders NEW YORK — Today, Ovarian Cancer Research Alliance (OCRFA), the nation’s leading ovarian cancer research, advocacy and patient support…
OCRFA Earns 4-Star Rating from Charity Navigator
(July 6, 2017) OCRFA is pleased to announce we have once again earned a 4-star rating from Charity Navigator, America’s largest independent charity evaluator…
Clinical Trial Shows Rucaparib Significantly Improved Progression-Free Survival in Ovarian Cancer Patients
(July 6, 2017) Clovis Oncology, Inc…
Action Alert: Protect Federal Funding for Ovarian Cancer Research
The White House has released a proposed budget for FY2018 that makes drastic cuts to the budgets for the National Institute of Health (NIH) and Centers for Disease Control and Prevention (CDC)…
OCRFA Awards $5.6 Million in Scientific Research Grants for 2017
(January 20, 2017) OCRFA has awarded $5.6 million in new scientific research grants for ovarian cancer, bringing our total investment in life-saving research to over $75 million…
Fighting Ovarian Cancer Through Patient Support and Education
Every year, 22,000 women are newly diagnosed with ovarian cancer. As OCRFA strives toward a cure and better treatments through research, we also provide patients and survivors with the care they need through our support and education programs…
Federal Funding for Ovarian Cancer: 2016 Highlights
As the voice for women with ovarian cancer on Capitol Hill, OCRFA fights to secure funding for ovarian cancer research and education at the federal level…
Five Important Discoveries from OCRFA-Funded Researchers in 2016
OCRFA-funded scientists are working hard to save women’s lives…
Kolker Fellowship Deadline Approaching
The Kolker Fellowship commemorates the legacy of pioneering health policy advocate Ann Kolker…
OCRFA Welcomes New Scientific Advisory Committee Members
OCRFA recently welcomed four new members to the Scientific Advisory Committee (SAC), our world-class group of leaders in the ovarian cancer field who review and approve all OCRFA research grants…
OCRFA applauds FDA’s statement on ovarian cancer screening test
On September 7th, the FDA issued an important safety communication about tests marketed as ovarian cancer screening tests, including the ROCA Test developed by Abcodia Incorporated…
Action Alert: Oral Chemotherapy Parity
Join us in asking Congress to pass oral chemotherapy parity legislation today. This legislation will ensure that patients have access to the best chemotherapy drugs available, including many personalized therapies…